Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SB225002 是一种有效的选择性 CXCR2 拮抗剂,抑制白介素 IL-8 与 CXCR2 的结合,IC50为 22 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 196 | 现货 | ||
5 mg | ¥ 437 | 现货 | ||
10 mg | ¥ 628 | 现货 | ||
25 mg | ¥ 1,260 | 现货 | ||
50 mg | ¥ 2,390 | 现货 | ||
100 mg | ¥ 3,630 | 现货 | ||
200 mg | ¥ 5,260 | 现货 | ||
500 mg | ¥ 8,170 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 438 | 现货 |
产品描述 | SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2. |
靶点活性 | CXCR2:22 nM |
体外活性 | SB225002表现出长效的镇痛效果,并减少小鼠模型中TNBS诱导的结肠炎.在兔子中,SB225002选择性阻断IL-8诱导的嗜中性粒细胞的边缘化.在小鼠肝内胆管细胞癌模型中,1 mg/kg i.p. SB225002抑制皮下移植肿瘤的生长. |
体内活性 | SB225002显示了作为微管抑制剂的抗肿瘤活性。SB225002大大降低了磷酸化ERK1/2的水平,并降低了WHCO1细胞的细胞增殖。SB225002在体外实验中,抑制GROα刺激的钙动员,并有效地抑制由IL-8和GROα诱导的人和兔嗜中性粒细胞趋化性。 |
激酶实验 | Radioligand Binding Experiments: Assays are performed in 96-well microtiter plates where the reaction mixture contains 1.0 μg/ml membrane protein in 20 mM Bis-Tris-propane, pH 8.0, with 1.2 mM MgSO4, 0.1 mM EDTA, 25 mM NaCl, and 0.03% CHAPS and SB 225002 (10 mM stock in Me2SO) added at the indicated concentrations, the final Me2SO concentration is <1% under standard binding conditions. Binding is initiated by addition of 0.25 nM 125I-IL-8 (2,200 Ci/mmol). After 1-h incubation at room temperature the plate is harvested using a Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1% polyethyleneimine, 0.5% BSA and washed three times with 25 mM NaCl, 10 mM Tris·HCl, 1 mM MgSO4, 0.5 mM EDTA, 0.03% CHAPS, pH 7.4. The filter is dried, sealed in a sample bag containing 10 ml of Wallac 205 Betaplate liquid scintillation fluid, and counted with a Wallac 1205 Betaplate liquid scintillation counter. |
细胞实验 | Three esophageal squamous cell carcinoma cell lines WHCO1, WHCO5, and WHCO6 originally established from surgical biopsies of primary esophageal squamous cell carcinomas are cultured in DMEM containing 10% FCS at 37°C in a humidified atmosphere of 5% CO2. MTT assays are carried out using the Cell Proliferation kit I. Briefly, 1.5 × 103 cells are plated in 96-well plates in a final volume of 180 μL DMEM per well. SB 225002 (antagonist of CXCR2, 400 nM) is added to cells and 0.001% DMSO (solvent) is added as a control. After the indicated incubation period, 18 μL of the MTT labeling reagent (final concentration 0.5 mg/mL) is added to each well and incubated for 4 hours in a humidified atmosphere. One hundred eighty microliters of the solubilization solution are added to each well and the plates were left overnight at 37°C. The spectrophotometric absorbance of samples is measured at 595 nm using a microtiter plate reader.(Only for Reference) |
分子量 | 352.14 |
分子式 | C13H10BrN3O4 |
CAS No. | 182498-32-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 65 mg/mL (184.6 mM)
Ethanol: 3 mg/mL (8.51 mM), Heating is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.8398 mL | 14.1989 mL | 28.3978 mL | 70.9945 mL |
5 mM | 0.568 mL | 2.8398 mL | 5.6796 mL | 14.1989 mL | |
DMSO | 10 mM | 0.284 mL | 1.4199 mL | 2.8398 mL | 7.0994 mL |
20 mM | 0.142 mL | 0.7099 mL | 1.4199 mL | 3.5497 mL | |
50 mM | 0.0568 mL | 0.284 mL | 0.568 mL | 1.4199 mL | |
100 mM | 0.0284 mL | 0.142 mL | 0.284 mL | 0.7099 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SB225002 182498-32-4 Autophagy GPCR/G Protein Immunology/Inflammation CXCR SB-225002 CXC chemokine receptors Inhibitor inhibit SB 225002 inhibitor